Dianthus Therapeutics, Inc. /DE/ (DNTH) Operating income 2016–2025
Dianthus Therapeutics, Inc. /DE/ (DNTH) annual operating income history from SEC filings — each fiscal year as reported.
-$177.9MFY2025 · since FY2016: -$9.3M → -$177.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$177.9M | -74.7% |
| FY2024 | -$101.9M | -111.5% |
| FY2023 | -$48.2M | -62.2% |
| FY2022 | -$29.7M | +60.2% |
| FY2021 | -$74.7M | +5.1% |
| FY2020 | -$78.7M | +5.1% |
| FY2019 | -$83.0M | -38.4% |
| FY2018 | -$60.0M | -67.8% |
| FY2017 | -$35.7M | -285.5% |
| FY2016 | -$9.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More DNTH financial trends
DNTH RevenueDNTH Net incomeDNTH Net marginDNTH Gross profitDNTH Gross marginDNTH Operating marginDNTH Operating cash flowDNTH Free cash flowDNTH Capital expendituresDNTH Return on equityDNTH Stock buybacksDNTH Dividends paidDNTH Total assetsDNTH Total liabilitiesDNTH Shareholders’ equityDNTH overview →